Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease

Core Insights - Monte Rosa Therapeutics is advancing MRT-6160, a VAV1-directed molecular glue degrader, which has shown promise in inhibiting colitis disease progression and reducing colon inflammation in preclinical models [2][3][6] - The company anticipates initiating a Phase 1 single ascending dose/multiple ascending dose study for MRT-6160 in mid-2024, with clinical data expected in Q1 2025 [1][3] Group 1: Preclinical Findings - MRT-6160 demonstrated an 85% reduction in disease progression in a murine T-cell transfer model of colitis compared to vehicle control, with a statistically significant p-value of <0.0001 [6] - The treatment led to decreased expression of pro-inflammatory cytokines and inflammatory-disease associated genes, including TNF and IL-17A in CD4+ T-cells [6][7] - VAV1, the target of MRT-6160, is a key signaling protein involved in T- and B-cell receptor activity, and its degradation has potential therapeutic implications for various autoimmune diseases [5][6] Group 2: Company Overview - Monte Rosa Therapeutics is a clinical-stage biotechnology company focused on developing molecular glue degrader medicines for serious diseases, including oncology and autoimmune conditions [8] - The company utilizes its QuEEN™ discovery engine, which combines AI-guided chemistry and structural biology, to identify and design highly selective MGDs [8] - Monte Rosa has established a strategic collaboration with Roche to develop MGDs targeting previously undruggable proteins in cancer and neurological diseases [8]